AI Research Report
Eli Lilly and Company (LLY) Stock Research — September 27, 2026
Created with Valarn by Joe (Valarn)Since this research was generated, 1 important thing has changed:
- •Congressional trades disclosed since the report: 1.
AI models share much of their training data and are not independent, so agreement between them is not a probability of being correct.
This research was generated on September 27, 2026. Markets and company information may have changed since then.
Growth strong, price premium, thin cushion
Bottom line
Growth is strong across regions and products, with solid margins. The stock trades at a premium and faces supply and flow headwinds.
LLY’s GLP‑1 engine continues to deliver outsized growth (TTM +65.8%; latest quarter +78.9% YoY) with breadth across geographies and segments, while margins remain elite (83.4% gross; 45.6% operating) and execution consistent (4/4 EPS beats). Valuation is growth‑backed with a forward P/E of 32.4x, a PEG of 0.42, and a current multiple below the 5‑year median band, though peer premiums and a 0.81% FCF yield mean limited cushion if growth slows. Consensus bakes in strong FY2026 EPS (36.58) and +35.8% revenue growth, and options imply a meaningful event window into the 10/29 print. Key watchpoints are any signs of GLP‑1 growth deceleration from the +99.3% Cardiometabolic baseline, operating‑margin slippage from 45.6%, or capacity‑driven allocation/guidance cuts.
What supports the view
- Top-line momentum is broad, with TTM revenue up 65.8%.
- Margins are durable, with operating margin at 45.6%.
- Financial strength shows through, with net debt/EBITDA at 1.06x.
What works against it
- Valuation looks stretched with forward P/E at 32.4x and a free-cash-flow yield of 0.8%.
- Revenue is heavily concentrated in Cardiometabolic Health (80.6% of sales), making it vulnerable to GLP-1 shocks.
- Manufacturing and flow risks could constrain growth or lead to guidance cuts.
Key catalysts
- Q3 2026 EarningsOct 29, 2026
Key risks
- GLP-1 concentrationCardiometabolic Health accounts for 80.6% of product revenue, heightening sensitivity to GLP-1 competition or pricing shocks.
- Manufacturing capacityCapacity increases may not keep up with demand, risking allocations or guidance cuts.
- Valuation and flowsPremium vs peers and a very low free-cash-flow yield leave little cushion if growth slows; forward metrics and cash flow expectations add risk.
- Macro/rate riskA sustained rise in rates could squeeze multiples and funding for growth.
The AI debate
21 AI specialists researched LLY; a bull and a bear researcher then argued it out over 3 rounds.
Bull caseLLY’s hypergrowth and elite margins, paired with a not-stretched forward multiple, set up attractive 12‑month risk/reward with multiple ways to win on execution and catalysts.
Bear caseLLY's premium valuation and extreme reliance on a single, decelerating-risk GLP-1 franchise leave little margin for error against a backdrop of insider selling and sector outflows.
AI research team
- Earnings
- Sector & Peer
- Quality & Moat
- Valuation
- Red Flags
- Options Flow
- Short Interest
- Congressional Trading
- Insider Activity
- +12 more
What should Valarn research next?
Research like a hedge fund—learn the why before you buy. Run it yourself, free.
This is the public research summary
The complete report includes the full AI debate, every specialist's research, the evidence behind each claim, options and insider analysis, backtesting and the advanced risk review.
Think the thesis is wrong?
Run your own research on LLY. If you publish it, readers can compare both reports side by side — where they agree, and where the evidence splits.
Challenge this researchValarn 1.0.0
Educational AI research only. Not financial, investment, legal, or tax advice. Not a recommendation to buy, sell, or hold any security. AI-generated and may be inaccurate or out of date. Consult a licensed advisor.